Argus Downgrades Pfizer (PFE) to Hold
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Argus downgraded Pfizer (NYSE: PFE) from Buy to Hold on a weaker outlook.
The analyst no longer expect PFE to achieve their former target price of $39 given recent pipeline setbacks, prospects for increased competition, and management’s decision to shelve its business separation plan.
The firm is lowering 2016 EPS estimate to $2.40 from $2.47, due mainly to the cancellation of Phase 3 trials of the company’s cholesterol-lowering drug. They are also lowering 2017 estimate to $2.57 from $2.65 based on expectations for higher costs and increased competition next year.
Shares of Pfizer closed at $31.07 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Argus Downgrades Sonoco Products (SON) to Hold
- Oppenheimer Raises Price Target on CarMax (KMX) to $72 Ahead of 3Q
- UBS Raises Price Target on Dick's Sporting Goods (DKS) to $69
Create E-mail Alert Related CategoriesAnalyst Comments, Downgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!